Treatment with von Willebrand factor concentrates is generally well tolerated.1, 2
Rare cases of thromboembolic events or the development of alloantibodies have been reported with some von Willebrand factor concentrates.3, 4 No thromboembolic events or inhibitory alloantibodies have been reported in clinical trials with wilate® in people with all von Willebrand disease types.5
Tolerability of wilate® has been demonstrated across 8 clinical trials in 155 patients with von Willebrand disease5 *
With 28 treatment-related adverse events reported in 17 patients
* Indication: Prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contra-indicated.
Inhibitory antibodies to von Willebrand factor
Tolerability of wilate® was rated very good or good >99% of infusions6
Tolerability has been confirmed in over 15 years of experience in the real-world setting, with approximately 1.8 billion international units of wilate® distributed wordwide5